Skip to Content

Amyris Gives Up Making Biofuels: Update

Humbled by production challenges, the company plans to scale back production goals, it told investors Thursday.
February 10, 2012

[See update below.]

An Amyris demonstration facility in Brazil. Credit: Noah Friedman-Rudovsky.

In its early years, biotech company Amyris described itself as a start-up “applying its proprietary breakthrough technologies to address major global health and energy challenges.” 

Its originally planned to make an anti-malaria drug, as well as renewable diesel and jet fuel, by feeding sugar to genetically-engineered microorganisms. Having spun off the anti-malaria technology to another company in 2008, yesterday Amyris said it’s giving up making fuels too. Instead, it will to focus on higher value products, such as moisturizers for cosmetics.  

The company learned firsthand just how difficult it is to achieve the kind of yields seen in lab tests in large-scale production. In an update call for investors, CEO John Melo said he is “humbled by the lessons we have learned.”

This is a common theme for advanced biofuels companies. Range Fuels, one of the first of the current crop of companies, recently went out of business. Others are giving up on making biofuels too, also hoping to break into markets for higher value chemicals. Although they may be able to get more money per liter of product, some experts warn that these markets are also highly competitive.

Amyris’s technology may still be used to make renewable fuels, but this will happen not at Amyris, but under joint ventures established with Total and Cosan. These ventures will need to build up their own production capacity, Melo told analysts.

On the same call, Melo told investors not to expect the company to produce as much product as it had previously promised. Amyris had said that in 2012 it would produce 40 to 50 million liters of farnesene, a fragrant oil that can be used for making various products including diesel. Melo said Amyris would stop making predictions about its production levels, turning its attention away from ramping up production and toward achieving consistent yields. He also said Amyris is indefinitely delaying plans for one of two large production facilities it was to have built this year. 

Not all biofuels companies are backing off from biofuels though. Mascoma, which has developed a process for making ethanol from cellulosic sources such as wood chips, announced in December that it had fully funded the construction of a cellulosic ethanol plant. Construction is expected to begin within a few months, to be completed by the end of 2013.

Update, 2/14/2012 :

Amyris wants to make clear that it isn’t giving up on its current, relatively small scale, biofuel production. Some of the farnesene Amyris makes is being used to make diesel fuel for buses in Brazil, and Amyris will continue to make farnesene for fuel until the joint ventures are up and running, says Joel Velasco, senior vice president for external relations. As Amyris adds more farnesene capacity this year, some of that, too, could be used for the production of fuel, he says.

While Amyris doesn’t disclose precisely how much fuel is made from its farnesene, based on the number of buses it supplies, Amyris seems to be making a few hundred thousand liters of fuel per year. Commercial fuel production, to make economic sense, typically needs to be on a much larger scale—hundreds of millions of liters per year.

Amyris had generated excitement in recent months when it announced would produce 40 to 50 million liters of farnesene in 2012, and build two plants with a total capacity of 150 million liters. Although Amyris had made clear that not all of the production would go to biofuels, the plants were some rare positive news in the advanced biofuels industry, which has been plagued by bankruptcies and delays.

But now Amyris has given up on its 40 to 50 million liter prediction, and indefinitely delayed construction on the larger of the two plants it had planned. Large scale biofuels production awaits construction of facilities by the joint venture companies. That construction seems unlikely to happen in the near term in light of the difficulties Amyris is having in achieving its announced goals this year. The promise of large scale biofuels is still some time off. 

Keep Reading

Most Popular

wet market selling fish
wet market selling fish

This scientist now believes covid started in Wuhan’s wet market. Here’s why.

How a veteran virologist found fresh evidence to back up the theory that covid jumped from animals to humans in a notorious Chinese market—rather than emerged from a lab leak.

light and shadow on floor
light and shadow on floor

How Facebook and Google fund global misinformation

The tech giants are paying millions of dollars to the operators of clickbait pages, bankrolling the deterioration of information ecosystems around the world.

masked travellers at Heathrow airport
masked travellers at Heathrow airport

We still don’t know enough about the omicron variant to panic

The variant has caused alarm and immediate border shutdowns—but we still don't know how it will respond to vaccines.

egasus' fortune after macron hack
egasus' fortune after macron hack

NSO was about to sell hacking tools to France. Now it’s in crisis.

French officials were close to buying controversial surveillance tool Pegasus from NSO earlier this year. Now the US has sanctioned the Israeli company, and insiders say it’s on the ropes.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.